Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1996 Nov;40(11):2447–2451. doi: 10.1128/aac.40.11.2447

In vivo efficacy of oral and intralesional administration of 2-substituted quinolines in experimental treatment of new world cutaneous leishmaniasis caused by Leishmania amazonensis.

A Fournet 1, M E Ferreira 1, A Rojas De Arias 1, S Torres De Ortiz 1, S Fuentes 1, H Nakayama 1, A Schinini 1, R Hocquemiller 1
PMCID: PMC163555  PMID: 8913444

Abstract

The antileishmanial efficacies of 2-n-propylquinoline, chimanines B and D, 2-n-pentylquinoline, 2-phenylquinoline, 2-(3,4-methylenedioxyphenylethyl) quinoline, and two total alkaloidal extracts of Galipea longiflora were evaluated in BALB/c mice infected with Leishmania amazonensis or Leishmania venezuelensis. Animals were treated for 4 to 6 weeks postinfection with a quinoline by the oral route at 50 mg/kg of body weight twice daily for 15 days or by five intralesional injections at intervals of 4 days with a quinoline at 50 mg/kg of body weight. The reference drug, N-methylglucamine antimonate (Glucantime), was administered by subcutaneous or intralesional injection (regimens of 14, 28, or 56 mg of pentavalent antimony [Sbv] per kg of body weight daily). Twice-daily oral treatment with chimanine B at 50 mg/kg resulted in a decrease in lesion weight by 70% (P < 0.001) and a decrease in the parasite loads by 95% (P < 0.001). Five injections of chimanine B at intervals of 4 days reduced the lesion weight by 74% and the parasite loads in the lesion by 90% compared with the values for the group of untreated mice. Subcutaneous administration of N-methylglucamine antimonate at 28 mg of Sbv kg per day for 15 days reduced the parasite burden by 95% (P < 0.001), and five intralesional injections at the same concentration reduced the parasite burden by 96% (P < 0.001). Other 2-substituted quinolines, 2-n-propylquinoline administered by the oral and intralesional routes, 2-phenylquinoline administered by the oral route, 2-n-pentylquinoline administered by intralesional injection, and two total alkaloidal extracts of G. longiflora administered by the oral route, had intermediate effects. These findings suggest that chimanine B may be chosen as a lead molecule in the development of oral therapy against leishmaniasis.

Full Text

The Full Text of this article is available as a PDF (227.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Afonso L. C., Scott P. Immune responses associated with susceptibility of C57BL/10 mice to Leishmania amazonensis. Infect Immun. 1993 Jul;61(7):2952–2959. doi: 10.1128/iai.61.7.2952-2959.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Albrecht H., Stellbrink H. J., Gross G., Berg B., Helmchen U., Mensing H. Treatment of atypical leishmaniasis with interferon gamma resulting in progression of Kaposi's sarcoma in an AIDS patient. Clin Investig. 1994 Dec;72(12):1041–1047. doi: 10.1007/BF00577752. [DOI] [PubMed] [Google Scholar]
  3. Altés J., Salas A., Riera M., Udina M., Galmés A., Balanzat J., Ballesteros A., Buades J., Salvá F., Villalonga C. Visceral leishmaniasis: another HIV-associated opportunistic infection? Report of eight cases and review of the literature. AIDS. 1991 Feb;5(2):201–207. [PubMed] [Google Scholar]
  4. Barral-Netto M., da Silva J. S., Barral A., Reed S. Up-regulation of T helper 2 and down-regulation of T helper 1 cytokines during murine retrovirus-induced immunodeficiency syndrome enhances susceptibility of a resistant mouse strain to Leishmania amazonensis. Am J Pathol. 1995 Mar;146(3):635–642. [PMC free article] [PubMed] [Google Scholar]
  5. Berenguer J., Moreno S., Cercenado E., Bernaldo de Quirós J. C., García de la Fuente A., Bouza E. Visceral leishmaniasis in patients infected with human immunodeficiency virus (HIV). Ann Intern Med. 1989 Jul 15;111(2):129–132. doi: 10.7326/0003-4819-111-2-129. [DOI] [PubMed] [Google Scholar]
  6. Buffet P. A., Sulahian A., Garin Y. J., Nassar N., Derouin F. Culture microtitration: a sensitive method for quantifying Leishmania infantum in tissues of infected mice. Antimicrob Agents Chemother. 1995 Sep;39(9):2167–2168. doi: 10.1128/aac.39.9.2167. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Fournet A., Barrios A. A., Muñoz V., Hocquemiller R., Cavé A., Bruneton J. 2-substituted quinoline alkaloids as potential antileishmanial drugs. Antimicrob Agents Chemother. 1993 Apr;37(4):859–863. doi: 10.1128/aac.37.4.859. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Fournet A., Gantier J. C., Gautheret A., Leysalles L., Munos M. H., Mayrargue J., Moskowitz H., Cavé A., Hocquemiller R. The activity of 2-substituted quinoline alkaloids in BALB/c mice infected with Leishmania donovani. J Antimicrob Chemother. 1994 Mar;33(3):537–544. doi: 10.1093/jac/33.3.537. [DOI] [PubMed] [Google Scholar]
  9. Grogl M., Thomason T. N., Franke E. D. Drug resistance in leishmaniasis: its implication in systemic chemotherapy of cutaneous and mucocutaneous disease. Am J Trop Med Hyg. 1992 Jul;47(1):117–126. doi: 10.4269/ajtmh.1992.47.117. [DOI] [PubMed] [Google Scholar]
  10. Grögl M., Oduola A. M., Cordero L. D., Kyle D. E. Leishmania spp.: development of pentostam-resistant clones in vitro by discontinuous drug exposure. Exp Parasitol. 1989 Jul;69(1):78–90. doi: 10.1016/0014-4894(89)90173-2. [DOI] [PubMed] [Google Scholar]
  11. Hill J. O., North R. J., Collins F. M. Advantages of measuring changes in the number of viable parasites in murine models of experimental cutaneous leishmaniasis. Infect Immun. 1983 Mar;39(3):1087–1094. doi: 10.1128/iai.39.3.1087-1094.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Ho J. L., Badaro R., Hatzigeorgiou D., Reed S. G., Johnson W. D., Jr Cytokines in the treatment of leishmaniasis: from studies of immunopathology to patient therapy. Biotherapy. 1994;7(3-4):223–235. doi: 10.1007/BF01878488. [DOI] [PubMed] [Google Scholar]
  13. Iwu M. M., Jackson J. E., Schuster B. G. Medicinal plants in the fight against leishmaniasis. Parasitol Today. 1994 Feb;10(2):65–68. doi: 10.1016/0169-4758(94)90398-0. [DOI] [PubMed] [Google Scholar]
  14. Munos M. H., Mayrargue J., Fournet A., Gantier J. C., Hocquemiller R., Moskowitz H. Synthesis of an antileishmanial alkaloid isolated from Galipea longiflora and of related compounds. Chem Pharm Bull (Tokyo) 1994 Sep;42(9):1914–1916. doi: 10.1248/cpb.42.1914. [DOI] [PubMed] [Google Scholar]
  15. Silva E. M., Bertho A. L., Mendonça S. C. Effect of in vivo depletion of CD4+ T cells on experimental infection of susceptible BALB/c mice with Leishmania amazonensis. Acta Trop. 1994 Feb;56(1):111–120. doi: 10.1016/0001-706x(94)90045-0. [DOI] [PubMed] [Google Scholar]
  16. Torre-Cisneros J., Villanueva J. L. Efficacy of liposomal amphotericin B in the treatment of visceral leishmaniasis in patients coinfected with the human immunodeficiency virus. Clin Infect Dis. 1995 Jan;20(1):191–191. doi: 10.1093/clinids/20.1.191. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES